Quotient Limited to Report Fiscal Fourth Quarter and Full Year 2021 Financial Results and Host Conference Call

Rhea-AI Summary

Quotient Limited (NASDAQ:QTNT) will announce its fiscal fourth quarter and full year financial results for the period ending March 31, 2021, before market open on June 1, 2021. A conference call will be held at 8:00 a.m. ET on the same day to discuss the results, with dial-in options provided for participants. Quotient, a leader in transfusion diagnostics, has developed the MosaiQ COVID-19 Antibody Microarray, which has received CE marking and FDA Emergency Use Authorization. The company is committed to improving diagnostic practices globally.

Positive

• The MosaiQ COVID-19 Antibody Microarray received FDA Emergency Use Authorization.
• Quotient's MosaiQ technology is expected to provide significant operational cost savings and efficiency improvements for laboratories.

Negative

• None.

JERSEY, Channel Islands, May 25, 2021 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced that financial results for its fiscal fourth quarter and full year ended March 31, 2021 will be released before market open on Tuesday, June 1, 2021.

Quotient will host a conference call to discuss its fiscal fourth quarter and full year financial results at 8:00 a.m. Eastern Time the same day. Participants may access the call by dialing 1-877-407-0784 in the U.S. or 1-201-689-8560 outside the U.S. The access code is 13719859. The conference call will be webcast live on the Company's website at www.quotientbd.com.

A replay of this conference call will be available through June 8, 2021 by dialing 1-844-512-2921 in the U.S. or 1-412-317-6671 outside the U.S. The replay access code is 13719859.

About Quotient Limited

Building on over 30 years of experience in transfusion diagnostics, Quotient is a commercial-stage diagnostics company committed to delivering solutions that reshape the way diagnostics is practiced. MosaiQ, Quotient’s proprietary multiplex microarray technology, offers the world’s first fully automated, consolidated testing platform, allowing for multiple tests across different modalities. MosaiQ is designed to be a game-changing solution, which Quotient believes will increase efficiencies, improve clinical practice, deliver significant workflow improvements, and operational cost savings to laboratories around the world. In response to the global effort to combat COVID-19, Quotient developed the MosaiQ COVID-19 Antibody Microarray which is CE marked and has received the U.S. FDA Emergency Use Authorization. Quotient's operations are based in Eysins, Switzerland, Edinburgh, Scotland and Newtown, Pennsylvania.

The Quotient logo and MosaiQ™ are registered trademarks or trademarks of Quotient Limited and its subsidiaries in various jurisdictions.

Contact: Peter Buhler, Chief Financial Officer, IR@quotientbd.com; +41 22 545 52 26

FAQ

When will Quotient Limited release its financial results for Q4 2021?

Quotient Limited will release its financial results for Q4 2021 on June 1, 2021, before market open.

What time is the conference call for Quotient Limited's financial results?

The conference call to discuss Quotient Limited's financial results will be held at 8:00 a.m. Eastern Time on June 1, 2021.

What is the significance of the MosaiQ technology developed by Quotient?

MosaiQ technology is designed to improve diagnostic efficiencies and has received FDA Emergency Use Authorization for its COVID-19 Antibody Microarray.

How can I access the replay of Quotient Limited's conference call?

The replay of Quotient Limited's conference call will be available until June 8, 2021, by calling 1-844-512-2921 in the U.S. or 1-412-317-6671 outside the U.S.